Clinical Trials in Varberg, Sweden

7 recruiting

Showing 18 of 8 trials

Recruiting
Phase 3

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Not Applicable

Evaluation of Primary Care Behavioral Health (PCBH) With the Addition of Self-help CBT - A Randomized Multicenter Trial

InsomniaPsychological DistressDepression+10 more
Linnaeus University1,242 enrolled4 locationsNCT04900064
Recruiting
Phase 3

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Karolinska Institutet750 enrolled32 locationsNCT03903835
Recruiting
Not Applicable

Aerobic Versus Leisure Group for Adolescents With Depression

Depressive Disorder, Major
Lund University Hospital122 enrolled4 locationsNCT05076214
Recruiting
Phase 2

Ixekizumab Diabetes Intervention Trial (I-DIT)

Type1 Diabetes Mellitus
Göteborg University127 enrolled17 locationsNCT04589325
Recruiting
Phase 3

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction
Uppsala University2,000 enrolled78 locationsNCT02901184
Recruiting
Phase 3

Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

DeathAtrial FibrillationChronic Kidney Diseases+6 more
Region Stockholm1,400 enrolled34 locationsNCT05679024
Recruiting
Phase 3

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Diffuse Large B Cell LymphomaDLBCL
Nordic Lymphoma Group300 enrolled69 locationsNCT04332822